Cancers are named primarily by two things: the type of tissue where they started and whether they are benign or malignant. A cancer that begins in the lining of the lung keeps its lung-origin name even if it later spreads to the liver or brain. This system of naming builds on Greek and Latin roots that describe the cell type involved, and understanding a few key suffixes unlocks the logic behind nearly every cancer name you’ll encounter.
The Suffix Tells You Benign or Malignant
The simplest rule in cancer naming is the ending of the word. Benign tumors, those that don’t invade surrounding tissue or spread, almost always end in “-oma.” A benign glandular tumor is an adenoma. A benign bone tumor is an osteoma. When those same tissues become malignant, the name changes to reflect the danger: a malignant glandular tumor becomes an adenocarcinoma, and a malignant bone tumor becomes an osteosarcoma.
This pattern holds across most of oncology. The prefix identifies the tissue (osteo- for bone, lipo- for fat, chondro- for cartilage), and the suffix tells you whether the growth is cancerous. There are exceptions, though. Lymphoma, melanoma, and mesothelioma all end in “-oma” but are malignant. These are quirks of medical history rather than logic, and they’re worth knowing so the suffix rule doesn’t mislead you.
The Six Major Categories
Every cancer falls into one of a handful of broad categories based on the type of cell it originates from. These categories form the backbone of how cancers are classified worldwide.
Carcinomas are cancers of epithelial tissue, the cells that line your organs, glands, and skin. They are by far the most common type. Breast cancer, lung cancer, colon cancer, prostate cancer, and bladder cancer are all carcinomas. Most carcinomas affect organs capable of secretion, like the breasts (which produce milk) or the lungs (which secrete mucus).
Sarcomas originate in supportive and connective tissues: bone, cartilage, muscle, fat, tendons, and blood vessels. Their names combine a tissue prefix with “-sarcoma.” Osteosarcoma starts in bone. Chondrosarcoma starts in cartilage. Leiomyosarcoma starts in smooth muscle. Liposarcoma starts in fat. Rhabdomyosarcoma starts in skeletal muscle. Angiosarcoma starts in blood vessels. Sarcomas are far less common than carcinomas but can occur almost anywhere in the body.
Leukemias are sometimes called “liquid cancers” or blood cancers. They originate in the bone marrow, where blood cells are produced. They’re further classified by how quickly they progress (acute or chronic) and which type of white blood cell is affected. Lymphocytic leukemia involves cells in the lymphoid line, while myelogenous leukemia involves the myeloid line.
Lymphomas develop in the lymphatic system, the network of nodes, vessels, and organs (including the spleen, tonsils, and thymus) that filters bodily fluids and produces infection-fighting white blood cells. The two main subcategories are Hodgkin lymphoma and non-Hodgkin lymphoma. Lymphomas can also arise in specific organs like the stomach, breast, or brain.
Myelomas originate in the plasma cells of bone marrow. Multiple myeloma, the most well-known type, affects plasma cells that normally produce antibodies.
The Name Stays With the Original Site
One of the most important rules in cancer naming is that a cancer keeps the name of its origin regardless of where it spreads. If breast cancer metastasizes to the bones, it is called metastatic breast cancer, not bone cancer. If lung cancer spreads to the brain, it remains lung cancer. This isn’t just a labeling preference. The cells in the new location still behave like cells from the original tissue, and treatments are chosen based on that origin.
Medical coding systems reinforce this. The standard practice is to code the site where the primary tumor originated, not the metastatic site. Even if the original tumor can’t be found, the classification system records the primary site as unknown rather than assigning it to wherever the metastases appeared.
How Staging Adds Detail to the Name
Beyond the basic name, cancers are described using the TNM staging system, the most widely used cancer staging method in the world. TNM stands for three variables:
- T (tumor): The size and extent of the primary tumor. T1 is small, T4 is large or has grown deeply into nearby tissues. T0 means no primary tumor can be found.
- N (nodes): Whether cancer has reached nearby lymph nodes, and how many. N0 means no lymph node involvement. N1 through N3 indicate increasing spread.
- M (metastasis): Whether the cancer has spread to distant parts of the body. M0 means it hasn’t. M1 means it has.
A cancer described as T1N0M0 is small, hasn’t reached lymph nodes, and hasn’t spread. T3N1M0 is larger, has reached some nearby lymph nodes, but hasn’t traveled to distant organs. These codes get combined with the cancer’s name to give a complete picture, like “stage II invasive ductal carcinoma, T2N1M0.”
Molecular Markers in Modern Names
Increasingly, cancer names include information about the genetic mutations or molecular features driving the tumor’s growth. This is because two cancers in the same organ can behave very differently depending on their underlying biology.
Breast cancer, for example, may be described as HER2-positive or hormone receptor-positive, because these features determine which therapies will work. Non-small cell lung cancer might be classified by whether it carries an ALK gene rearrangement or an EGFR mutation. Melanoma treatment often depends on whether the tumor carries a BRAF V600E mutation. These molecular descriptors are now layered onto the traditional tissue-based name, creating more precise labels like “BRAF-mutant metastatic melanoma” or “ALK-positive non-small cell lung cancer.”
The World Health Organization maintains the official international classification, published through the International Agency for Research on Cancer. The current series spans fourteen volumes organized by body system, from breast tumors to central nervous system tumors, and the classification is regularly updated as molecular understanding evolves.
Cancers Named After People
Some cancers carry the name of the person who first described them. Hodgkin lymphoma is named after Thomas Hodgkin. Wilms tumor honors Max Wilms. Kaposi sarcoma takes its name from Moritz Kaposi. Lynch syndrome, a hereditary condition that raises the risk of colon and other cancers, is named after Henry Lynch.
These eponymous names remain popular because they’re short and easy to remember. But they’ve also drawn criticism for being imprecise, since a person’s name tells you nothing about the disease itself. Some eponyms associated with Nazi-era scientists have fallen out of use for ethical reasons. Still, many persist alongside their more technical alternatives, and you’re likely to encounter both in medical conversations.
Putting a Cancer Name Together
When you see a full cancer name, you can now break it into layers. Take “stage III HER2-positive invasive ductal carcinoma of the breast, T3N1M0.” Working through it: carcinoma tells you it started in epithelial (lining) tissue. Ductal means specifically in the milk ducts. Invasive means it has grown beyond the duct walls. HER2-positive identifies a molecular feature that guides treatment. T3N1M0 tells you the tumor is relatively large and has reached nearby lymph nodes but hasn’t spread to distant organs. Stage III summarizes the overall severity.
Each layer of the name carries information that helps determine prognosis and treatment. The system can seem dense at first, but it follows a consistent logic: start with the tissue type, add the location, note how far it’s spread, and increasingly, identify the molecular features that make it unique.